Leerink Partnrs Predicts Immatics’ Q1 Earnings (NASDAQ:IMTX)

Immatics (NASDAQ:IMTX) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Immatics in a research note issued to investors on Thursday, March 27th. Leerink Partnrs analyst J. Chang expects that the company will earn ($0.39) per share for the quarter. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS and Q4 2025 earnings at ($0.41) EPS.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research report on Tuesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Immatics currently has an average rating of “Buy” and an average target price of $16.67.

Immatics Stock Performance

Shares of Immatics stock opened at $4.00 on Monday. Immatics has a fifty-two week low of $3.88 and a fifty-two week high of $13.77. The company has a market capitalization of $477.42 million, a P/E ratio of -6.06 and a beta of 0.83. The company has a fifty day moving average of $4.91 and a 200 day moving average of $7.31.

Hedge Funds Weigh In On Immatics

Hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its holdings in Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock valued at $1,880,000 after acquiring an additional 13,997 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Immatics by 3.5% during the third quarter. Wasatch Advisors LP now owns 872,511 shares of the company’s stock valued at $9,955,000 after purchasing an additional 29,239 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Immatics in the third quarter worth about $298,000. Quarry LP lifted its position in shares of Immatics by 29.4% in the third quarter. Quarry LP now owns 11,000 shares of the company’s stock worth $126,000 after buying an additional 2,500 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Immatics by 11.2% in the third quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after buying an additional 22,710 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.